SOUTHERN TRUST COMPANY, INC ACCT.
For the Period 3/1113 to 3/31/13
Original Net Capital Called Net Distributions Estimated
Commitment Amount Since Inception Since Inception Value
Other Private Investments
P CALUMET SPECIALTY PRODUCTS PARTNERS 0.00
L P.
131476-10-3 CLMT
Amounts shown above under "Estimated Value" for private equity funds are estimates based on the latest fund values received from each underlying fund, which value may be as of a
date (underlying fund value date) prior to the period covered by this statement. The values provided by the underlying fund have been adjusted for any cash flows between your account
and such fund that have occurred subsequent to the underlying fund value date to derive the "Estimated Value". Therefore, such "Estimated Value" may not reflect the value of your
interest shown on any fund's actual books and records as of the date of this statement. For additional information, please contact your J.P. Morgan representative.
For private equity funds, amounts shown under "Estimated Value" are based on estimates provided by the underlying funds that are generally presented on a US GAAP basis, which
records investments at fair value, or 'marked-to-marker. Most of these underlying funds also present their audited financial statements on a US GAAP basis (i.e., "marked-to-market").
However, some of these underlying funds present their audited financial statements using the Income Tax Basis of Accounting, which records Investments -at cost" based on the accrual
basis of accounting for Federal income taxes. Virtiere the underlying fund provides periodic estimates on a "marked-to-market' basis but reflects investments "at cost" in its audited
financial statements, the marked-to-market "Estimated Value" shown herein for a private equity fund may be materially different from the value reflected on such fund's audited financial
statements (which are also based on the audited financial statements of the underlying fund).
J.P Morgan Account Page 6 of 14 Consolidated Statement Page 9
Confidential Treatment Requested by JPMorgan JPM-SDNY-00023893
Chase
CONFIDENTIAL SDNY_GM_00293091
EFTA01500015